Peripheral T-cell lymphomas: analysis of histology, staging and response to treatment of 208 cases at a single institution

References

• Foss FM, Zinzani PL, Vose JM, et al. Peripheral T-cell lymphoma. Blood 2011;117:6756–6767.
   PubMed Web of Science ®Google Scholar
• Mourad N, Mounier N, Briere J, et al. Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d’Etude des Lymphomes de l’Adulte (GELA) trials. Blood 2008;111:4463–4470.
   PubMed Web of Science ®Google Scholar
• Savage KJ. Therapies for peripheral T-cell lymphomas. Hematology Am Soc Hematol Educ Program 2011;1:515–524.
   Web of Science ®Google Scholar
• O’Connor OA, Pro B, Pinter-Brown L, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol 2011;29:1182–1189.
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C, Gaulard P, Lepage E, et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d’Etudes des Lymphomes de l’Adulte (GELA). Blood 1998;92:76–82.
   Google Scholar
• Weisenburger DD, Savage KJ, Harris NL, et al. Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood 2011;117:3402–3408.
   PubMed Web of Science ®Google Scholar
• Yamaguchi M. Current and future management of NK/T-cell lymphoma based on clinical trials. Int J Hematol 2012;96:562–571.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.
   Web of Science ®Google Scholar
• Voog E, Sebban C, Biron P, et al. A prospective study of the LMB regimen for diffuse large cell non Hodgkin's lymphoma in adults. Leuk Lymphoma 2000;36:525–532.
   PubMed Web of Science ®Google Scholar
• Suzumiya J, Ohshima K, Tamura K, et al. The International Prognostic Index predicts outcome in aggressive adult T-cell leukemia/lymphoma: analysis of 126 patients from the International Peripheral T-Cell Lymphoma Project. Ann Oncol 2009;20:715–721.
   PubMed Web of Science ®Google Scholar
• Gallamini A, Stelitano C, Calvi R, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 2004;103:2474–2479.
   PubMed Web of Science ®Google Scholar
• Sibon D, Fournier M, Briere J, et al. Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d’Etude des Lymphomes de l’Adulte trials. J Clin Oncol 2012;30:3939–3946.
   PubMed Web of Science ®Google Scholar
• Gutierrez-Garcia G, Garcia-Herrera A, Cardesa T, et al. Comparison of four prognostic scores in peripheral T-cell lymphoma. Ann Oncol 2011;22:397–404.
   PubMed Web of Science ®Google Scholar
• Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008;26:4124–4130.
   PubMed Web of Science ®Google Scholar
• Simon A, Peoch M, Casassus P, et al. Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95.. Br J Haematol 2010;151:159–166.
   PubMed Web of Science ®Google Scholar
• Schmitz N, Trumper L, Ziepert M, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood 2010; 116:3418–3425.
   PubMed Web of Science ®Google Scholar
• d’Amore F, Relander T, Lauritzsen GF, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol 2012;30:3093–3099.
   PubMed Web of Science ®Google Scholar
• Reimer P. Impact of autologous and allogeneic stem cell transplantation in peripheral T-cell lymphomas. Adv Hematol 2010; 2010:320624.
   PubMedGoogle Scholar
• le Gouill S, Milpied N, Buzyn A, et al. Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. J Clin Oncol 2008;26:2264–2271.
   PubMed Web of Science ®Google Scholar
• Corradini P, Dodero A, Zallio F, et al. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol 2004;22:2172–2176.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Pro B, Prince HM, et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol 2012;30:631–636.
   PubMed Web of Science ®Google Scholar
• Dueck G, Chua N, Prasad A, et al. Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma. Cancer 2010;116:4541–4548.
   PubMed Web of Science ®Google Scholar
• Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 2012;30: 2190–2196.
   PubMed Web of Science ®Google Scholar